The BRAFV600E mutation, which renders BRAF constitutively active with a 500-fold increase in kinase activity compared to wild-type BRAF [5], represents approximately 90% of all BRAF mutations observed in colon cancer patients. The gene discussed is BRAF; the disease is colonic neoplasm.